| Overview |
| bs-12421R-APC |
| 14-3-3 gamma Polyclonal Antibody, APC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Sheep, Horse, Rabbit, Zebrafish |
| Specifications |
| APC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human 14-3-3 gamma |
| 31-130/247 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7532 |
| Cytoplasm |
| 14 3 3 protein gamma; 14 3 3 protein gamma subtype; 14 3 3gamma; 14-3-3 protein gamma; 1433G_HUMAN; 3 monooxygenase/tryptophan 5 monooxgenase activation protein gamma polypeptide; KCIP 1; KCIP-1; KCIP1; N-terminally processed; Protein kinase C inhibitor protein 1; Tyrosine 3 monooxygenase/tryptophan 5 monooxygenase activation protein gamma polypeptide; YWHAG. |
| 14-3-3 proteins regulate many cellular processes relevant to cancer biology, notably apoptosis, mitogenic signaling and cell-cycle checkpoints. Seven isoforms comprise this family of signaling intermediates, denoted 14-3-3 b, g, e, z, h, q and s. 14-3-3 proteins form dimers that present two binding sites for ligand proteins, thereby bringing together two proteins that may not otherwise associate. These ligands largely share a 14-3-3 consensus binding motif and exhibit serine/threonine phosphorylation. 14-3-3 proteins function in broad regulation of these ligand proteins; by cytoplasmic sequestration, occupation of interaction domains and import/export sequences, prevention of degradation, activation/repression of enzymatic activity, and facilitation of protein modification. Loss of expression contributes to a vast array of pathogenic cellular activities. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz